Multimodal molecular imaging of integrin avb3 for in vivo detection of pancreatic cancer

Journal of Nuclear Medicine

Volumn 55, Issue 3, 2014, Pages 446-451

  Trajkovic Arsic, Marija ^a   Mohajerani, Pouyan ^b   Sarantopoulos, Athanasios ^b   Kalideris, Evdokia ^a   Steiger, Katja ^a   Esposito, Irene ^a   Ma, Xiaopeng ^b   Themelis, George ^b   Burton, Neal ^b   Michalski, Christoph W ^a   Kleeff, Jörg ^a   Stangl, Stefan ^a   Beer, Ambros J ^a   Pohle, Karolin ^a,c   Wester, Hans Jürgen ^c   Schmid, Roland M ^a   Braren, Rickmer ^a   Ntziachristos, Vasilis ^b   Siveke, Jens T ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fluorescence molecular tomography; Genetically engineered mice; Pancreatic cancer; Positron emission tomography

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4 BIS[ACETIC ACID] 7 [2 GLUTARIC ACID] ARGINYLGLYCYLASPARTIC ACID GA 68; INTEGRISENSE 680; RADIOISOTOPE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG ACCUMULATION; DRUG DISTRIBUTION; EARLY DIAGNOSIS; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; MULTIMODAL IMAGING; NONHUMAN; PANCREAS ADENOCARCINOMA; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRAM FEASIBILITY; PROTEIN EXPRESSION; TUMOR CELL; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; FEASIBILITY STUDY; FLUORESCENCE MOLECULAR TOMOGRAPHY; GENE EXPRESSION REGULATION; GENETICALLY ENGINEERED MICE; INTEGRIN ΑVΒ3; INTRAOPERATIVE PERIOD; METABOLISM; PANCREAS CANCER; PANCREAS TUMOR; SCINTISCANNING; TOMOGRAPHY; TUMOR CELL LINE;

FLUORESCENCE MOLECULAR TOMOGRAPHY; GENETICALLY ENGINEERED MICE; INTEGRIN ΑVΒ3; PANCREATIC CANCER; POSITRON EMISSION TOMOGRAPHY;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; INTRAOPERATIVE PERIOD; MICE; MULTIMODAL IMAGING; OPTICAL IMAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY;

EID: 84899486268     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129619     Document Type: Article

References (33)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
2. Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: an overview. J Gastrointest Oncol. 2011;2:168-174.
3. Herrmann K, Erkan M, Dobritz M, et al. Comparison of 39-deoxy-39-[18F] fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging. 2012;39:846-851.
4. Nguyen NQ, Bartholomeusz DF. 18F-FDG-PET/CT in the assessment of pancreatic cancer: is the contrast or a better-designed trial needed? J Gastroenterol Hepatol. 2011;26:613-615.
5. Ntziachristos V. Going deeper than microscopy: the optical imaging frontier in biology. Nat Methods. 2010;7:603-614.
6. Keereweer S, Kerrebijn JD, van Driel PB, et al. Optical image-guided surgery: where do we stand? Mol Imaging Biol. 2011;13:199-207.
7. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first inhuman results. Nat Med. 2011;17:1315-1319.
8. Keliher EJ, Reiner T, Earley S, et al. Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia. 2013;15:684-693.
9. Eser S, Messer M, Eser P, et al. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci USA. 2011;108:9945-9950.
10. Cruz-Monserrate Z, Abd-Elgaliel WR, Grote T, et al. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut. 2012;61:1315-1322.
11. Neesse A, Hahnenkamp A, Griesmann H, et al. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut. 2013;62:1034-1043.
12. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
13. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev. 2008;27:631-644.
14. Desgrosellier JS, Barnes LA, Shields DJ, et al. An integrin avb3-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009; 15:1163-1169.
15. Hosotani R, Kawaguchi M, Masui T, et al. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas. 2002;25:e30-e35.
16. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F] Galacto-RGD identifies the level of integrin avb3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
17. Knetsch PA, Petrik M, Griessinger CM, et al. [68Ga]NODAGA-RGD for imaging avb3 integrin expression. Eur J Nucl Med Mol Imaging. 2011;38:1303-1312.
18. Nakhai H, Sel S, Favor J, et al. Ptf1a is essential for the differentiation of GABAergic and glycinergic amacrine cells and horizontal cells in the mouse retina. Development. 2007;134:1151-1160.
19. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437-450.
20. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14:994-1004.
21. Ale A, Ermolayev V, Herzog E, Cohrs C, de Angelis MH, Ntziachristos V. FMTXCT: in vivo animal studies with hybrid fluorescence molecular tomography-Xray computed tomography. Nat Methods. 2012;9:615-620.
22. Schulz RB, Ale A, Sarantopoulos A, et al. Hybrid system for simultaneous fluorescence and x-ray computed tomography. IEEE Trans Med Imaging. 2010;29: 465-473.
23. Themelis G, Yoo JS, Soh KS, Schulz R, Ntziachristos V. Real-time intraoperative fluorescence imaging system using light-absorption correction. J Biomed Opt. 2009;14:064012.
24. Sarantopoulos A, Themelis G, Ntziachristos V. Imaging the bio-distribution of fluorescent probes using multispectral epi-illumination cryoslicing imaging. Mol Imaging Biol. 2011;13:874-885.
25. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of avb3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
26. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
27. Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga-NODAGARGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39:777-784.
28. Themelis G, Harlaar NJ, Kelder W, et al. Enhancing surgical vision by using real-time imaging of avb. Ann Surg Oncol. 2011;18:3506-3513.
29. Harlaar NJ, Kelder W, Sarantopoulos A, et al. Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an avb3-integrin targeted agent. Gynecol Oncol. 2013;128:590-595.
30. Wu Y, Cai W, Chen X. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol. 2006;8:226-236.
31. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin avb3 in brain tumor xenografts. Cancer Res. 2004;64:8009-8014.
32. Wang W, Ke S, Wu Q, et al. Near-infrared optical imaging of integrin avb3 in human tumor xenografts. Mol Imaging. 2004;3:343-351.
33. Kossodo S, Pickarski M, Lin SA, et al. Dual in vivo quantification of integrintargeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol. 2010;12:488-499.